Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
28.18
-0.09 (-0.32%)
At close: Mar 4, 2026, 4:00 PM EST
28.18
0.00 (0.00%)
After-hours: Mar 4, 2026, 4:56 PM EST
Travere Therapeutics Revenue
In the year 2025, Travere Therapeutics had annual revenue of $490.73M with 110.45% growth. Travere Therapeutics had revenue of $129.69M in the quarter ending December 31, 2025, with 73.41% growth.
Revenue (ttm)
$490.73M
Revenue Growth
+110.46%
P/S Ratio
5.34
Revenue / Employee
$987,380
Employees
497
Market Cap
2.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 490.73M | 257.55M | 110.45% |
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
| Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | 175.34M | 11.09M | 6.75% |
| Dec 31, 2018 | 164.25M | 9.31M | 6.01% |
| Dec 31, 2017 | 154.94M | 21.35M | 15.98% |
| Dec 31, 2016 | 133.59M | 33.70M | 33.74% |
| Dec 31, 2015 | 99.89M | 71.69M | 254.19% |
| Dec 31, 2014 | 28.20M | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Apellis Pharmaceuticals | 1.00B |
| Adaptive Biotechnologies | 276.98M |
| Arcus Biosciences | 247.00M |
| Beam Therapeutics | 139.74M |
| Liquidia | 69.22M |
| Wave Life Sciences | 42.73M |
| Immunome | 9.68M |
| Dianthus Therapeutics | 3.08M |
TVTX News
- 8 days ago - Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms - Seeking Alpha
- 12 days ago - Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 20 days ago - Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 21 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit - Business Wire
- 4 weeks ago - Travere Therapeutics: Filspari's FSGS Approval Chance Is Higher Than You Think - Seeking Alpha
- 5 weeks ago - TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses - GlobeNewsWire